Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367056 | 1.00 | FABP5 (0.48) | FABP5FABP7TSHRKMT2AALDH1A1 | |
| SCHEMBL31532292 | 1.00 | FABP5 (0.48) | FABP5FABP7TSHRKMT2AALDH1A1 | |
| SCHEMBL29883515 | 0.80 | TSHR (0.42) | FABP5FABP7TSHRKMT2AALDH1A1 | |
| SCHEMBL3515128 | 0.80 | TSHR (0.42) | FABP5FABP7TSHRKMT2AALDH1A1 | |
| SCHEMBL4611910 | 0.79 | KMT2A (0.49) | TSHRKMT2AEPHX2 | |
| SCHEMBL2774790 | 0.76 | FABP5 (0.48) | FABP5FABP7TSHRKMT2AEPHX2 | |
| SCHEMBL789074 | 0.76 | FABP5 (0.48) | FABP5FABP7TSHRKMT2AEPHX2 | |
| SCHEMBL29430507 | 0.76 | FABP5 (0.48) | FABP5FABP7TSHRKMT2AEPHX2 | |
| SCHEMBL5227458 | 0.75 | GPBAR1 (0.51) | FABP5FABP7TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL274968 | 0.75 | GPBAR1 (0.51) | FABP5FABP7TSHRRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025160177-A9 | COMPOSITIONS AND METHODS FOR ORGAN AND CELL TARGETED DELIVERY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4596566-A1 | COMPOUND PRODUCTION METHOD | The University of Tokyo (JP) | 2025-08-06 | — | — | EP | disclosed |
| CN-119968380-A | Process for producing compound | 国立大学法人东京大学 | 2025-05-09 | — | — | CN | disclosed |
| US-20240190924-A1 | Synthesis of Gamma Peptide Nucleic Acid Monomers and Oligomers, and Applications Therefor | CARNEGIE MELLON UNIVERSITY | 2024-06-13 | — | — | US | disclosed |
| US-11970512-B2 | Amphotericin B derivatives with improved therapeutic index | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-04-30 | — | — | US | disclosed |
| WO-2024071320-A1 | COMPOUND PRODUCTION METHOD | 国立大学法人東京大学 | 2024-04-04 | — | — | WO | disclosed |
| EP-3596089-B1 | ANTIBACTERIAL COMPOUNDS | UNIV NOTTINGHAM (GB) | 2023-12-06 | — | — | EP | disclosed |
| CN-110407898-B | Amphotericin B derivatives with improved therapeutic index | 伊利诺伊大学评议会 | 2023-12-01 | — | — | CN | disclosed |
| US-20230097883-A1 | ERGOTHIONEINE PET COMPOUNDS AND METHODS OF USE THEREOF | VANDERBILT UNIVERSITY | 2023-03-30 | — | — | US | disclosed |
| US-20230082311-A1 | DRUG FOR CURATIVE THERAPY OF INTRACTABLE HEREDITARY RENAL ALPORT SYNDROME | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2023-03-16 | — | — | US | disclosed |
| US-20230016424-A1 | HYBRID AMIDE DERIVATIVES OF AMPHOTERICIN B | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2023-01-19 | — | — | US | disclosed |
| US-20230000891-A1 | HYBRID AMPHOTERICIN B DERIVATIVES WITH REDUCED TOXICITY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2023-01-05 | — | — | US | disclosed |
| US-11447524-B2 | Multifunction cyclic peptide polymer nanomaterials | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022187216-A1 | SYNTHESIS OF GAMMA PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS, AND APPLICATIONS THEREFOR | CARNEGIE MELLON UNIVERSITY (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-3261639-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INT CORPORATION (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4029514-A1 | DRUG FOR CURATIVE THERAPY OF INTRACTABLE HEREDITARY RENAL ALPORT SYNDROME | National University Corporation Kumamoto University (JP) | 2022-07-20 | — | — | EP | disclosed |
| CN-114761033-A | Medicament for radical therapy of refractory hereditary nephrotic Alport syndrome | 国立大学法人熊本大学 | 2022-07-15 | — | — | CN | disclosed |
| CN-114555094-A | Mixed amide derivatives of amphotericin B | 伊利诺伊大学评议会 | 2022-05-27 | — | — | CN | disclosed |
| CN-114502173-A | Mixed amphotericin B derivatives with reduced toxicity | 伊利诺伊大学评议会 | 2022-05-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230016424-A1 | HYBRID AMIDE DERIVATIVES OF AMPHOTERICIN B | AADAC, NAAA, NAT10 | FABP5 4064/4885FABP7 2100/4885TSHR 3576/4885 |
| US-20240190924-A1 | Synthesis of Gamma Peptide Nucleic Acid Monomers and Oligomers, and Applications Therefor | POLL, PCNA, POLQ | FABP5 2441/4885FABP7 566/4885TSHR 3133/4885 |
| US-20230097883-A1 | ERGOTHIONEINE PET COMPOUNDS AND METHODS OF USE THEREOF | GPX1, TSPO, GSTO1 | FABP5 871/4885FABP7 104/4885TSHR 2682/4885 |
| US-20230000891-A1 | HYBRID AMPHOTERICIN B DERIVATIVES WITH REDUCED TOXICITY | ERG28, PAICS, CERT1 | FABP5 4337/4885FABP7 2352/4885TSHR 3983/4885 |
| US-20230082311-A1 | DRUG FOR CURATIVE THERAPY OF INTRACTABLE HEREDITARY RENAL ALPORT SYNDROME | FKBP3, FKBP4, ATG4A | FABP5 1943/4885FABP7 3437/4885TSHR 4873/4885 |
| US-11447524-B2 | Multifunction cyclic peptide polymer nanomaterials | NGLY1, PTMS, PNISR | FABP5 4618/4885FABP7 3893/4885TSHR 1236/4885 |
| US-11970512-B2 | Amphotericin B derivatives with improved therapeutic index | C9, AMPD3, C5 | FABP5 1398/4885FABP7 2223/4885TSHR 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.